News stories about Mednax (NYSE:MD) have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Mednax earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.9285415703298 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

Mednax (NYSE MD) traded down $1.42 during trading on Monday, reaching $48.49. 2,399,365 shares of the company’s stock traded hands, compared to its average volume of 1,052,275. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37. The firm has a market capitalization of $4,670.00, a price-to-earnings ratio of 15.26, a price-to-earnings-growth ratio of 1.61 and a beta of 0.32. Mednax has a 12-month low of $40.56 and a 12-month high of $72.13.

Mednax (NYSE:MD) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting analysts’ consensus estimates of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The firm had revenue of $868.95 million during the quarter, compared to analyst estimates of $864.78 million. During the same quarter last year, the business posted $1.09 EPS. The company’s revenue was up 4.9% on a year-over-year basis. analysts predict that Mednax will post 3.1 EPS for the current fiscal year.

A number of research analysts recently commented on the stock. Citigroup Inc. lowered their price objective on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. Robert W. Baird raised their price objective on shares of Mednax from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Jefferies Group LLC reiterated a “hold” rating and set a $44.00 price objective on shares of Mednax in a research note on Friday, November 3rd. KeyCorp set a $51.00 price target on shares of Mednax and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets began coverage on shares of Mednax in a research report on Monday, October 16th. They issued a “market perform” rating and a $46.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $54.50.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Mednax (MD) Share Price” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/20/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-mednax-md-share-price.html.

In related news, Director Cesar L. Alvarez sold 10,668 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total value of $454,350.12. Following the completion of the transaction, the director now owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.